LEADER 01473nam--2200421---450-
001 990002679110203316
005 20080111092736.0
010   $a92-9168-168-7
035   $a000267911
035   $aUSA01000267911
035   $a(ALEPH)000267911USA01
035   $a000267911
100   $a20051027h2004----km-y0itay0103----ba
101   $aeng
102   $aLU
105   $aa|||||||001yy
200 1 $aHepatitis C and injecting drug use$eimpact, costs and policy options$feditors, Johannes Jager ... [et al.]
210   $aLuxembourg$cOffice for Official Publications of the European Communities$dcopyr. 2004
215   $a389 p.$cill.$d23 cm
225 2 $aEMCDDA monographs
300   $aIn testa al front.: European Monitoring Centre for Drugs and Drug Addiction
410 0 $12001$aEMCDDA monographs
606 0 $aDroghe$xUso$yPaesi dell'Unione europea
676   $a362.293094
699   $a02.04$bProblemi sociali
702  1$aJAGER,$bJohannes
710 02$aOSSERVATORIO EUROPEO DELLE DROGHE E DELLE TOSSICODIPENDENZE$0547105
801  0$aIT$bsalbc$gISBD
912   $a990002679110203316
951   $aCDE 02.04 (VI)$bCDE 187$cCDE 02.04$d00121738
959   $aBK
969   $aCDE
979   $aMARIASEN$b90$c20051027$lUSA01$h1334
979   $aCDE$b90$c20051114$lUSA01$h1014
979   $aMARIAS$b90$c20080111$lUSA01$h0927
979   $aMARIAS$b90$c20080305$lUSA01$h0852
996   $aHepatitis C and injecting drug use$91002525
997   $aUNISA